Experiment 634998
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | SAUDREAU,F: SERISE,IM: PILLET,J: MAIZA,D: MERCIER,V: KRETZ,JG: THIBERT,A:. (1989). EFFICIENCY OF GINKGO-BILOBA EXTRACT IN TREATMENT OF STAGE III (FONTALNE CLASSIFICATION) CHRONIC OCCULUSIVE ARTERIAL DISEASES OF THE LOWER LIMBS.. 14() |
| Amount utilized | |
| Compound isolated | |
| Disease | A CONTROLLED TRIAL OF GINKGO-BILOBA EXTRACT IN INJECTABLE FORM (TANADAN 50 MG, A LYOPHILISATE FOR PARENTERAL USE) WAS CARRIED OUT VERSUS A PLACEBO AS PREOPERATIVE MEDICAL TREATMENT OF STAGE III (FONTAINE CLASSIFICATION)CHRONIC OCCLUSIVE ARTERIAL DISEASES OF THE LOWER LIMBS (WITH PAIN IN DECUBITUS). THE 64 MEN AND WOMEN PATIENTS IN THIS MULTICENTER STUDY (32 IN EACH GROUP) WERE OVER 18 YEARS OF AGE AND HAD A CULTURAL AND INTELLECTUAL LEVEL AS WELL AS A PHYSICAL CONDITION ALLOWING THEM TO PLAY AN ACTIVE ROLE IN THE EXPERIMENT (SELF-EVALUATION OF PAIN). DURING 8 DAYS THEY RECEIVED 2 DAILY INFUSIONS OF 500 CC OF NORMAL SALINE SOLUTION CONTAINING EITHER 100 MG OF GINKGO-BILOBA EXTRACT OR A PLACEBO OF IDENTICAL APPEARANCE, DURING THIS PERIOD, ANTICOAGULANTS WERE AUTHORIZED; HEMODILUTION, VASOACTIVE DRUGS AND PLATELET ANTI-AGGREGATES WERE FORBIDDEN; PENTAZOCINE (FORTAL, 50-MG TABLETS) COMPARISON OF THE GROUPS SHOWED A STATISTICALLY SIGNIFICANT SUPERIORITY P-0.4 OF THE EXTRACT. A COMMERCIAL PRODUCT, TANAKAN, WAS USED. |
| Dose amount | 200.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | LYOPHILIZED EXTRACT |
| Gender | GIVEN TO BOTH SEXES |